0
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-first-quarter-and-interim-january-march-2025-financial-results/
"Financial Performance
Q1 2025 product sales of IDEFIRIX® totaled 65.7 MSEK representing a 39 percent increase over Q1 2024 (47.4 MSEK). Revenue for the first quarter 2025 totaled 66.3 MSEK. The addition of new sites using IDEFIRIX combined with growing repeat utilization contributed to the performance. Hansa expects to see continued strong year-on-year product sales growth despite continued quarterly product sales fluctuation due to variations in European kidney allocation systems, which impacts the availability of organs for patients."
https://www.hansabiopharma.com/media/press-releases/2025/hansa-biopharma-reports-first-quarter-and-interim-january-march-2025-financial-results/
"Financial Performance
Q1 2025 product sales of IDEFIRIX® totaled 65.7 MSEK representing a 39 percent increase over Q1 2024 (47.4 MSEK). Revenue for the first quarter 2025 totaled 66.3 MSEK. The addition of new sites using IDEFIRIX combined with growing repeat utilization contributed to the performance. Hansa expects to see continued strong year-on-year product sales growth despite continued quarterly product sales fluctuation due to variations in European kidney allocation systems, which impacts the availability of organs for patients."
24/4 2025 08:16 exitnu 0126043 Vækst i omsætning: Den samlede omsætning i 1. kvartal 2025 nåede 66,3 MSEK, en stigning på 18% år-til-år. IDEFIRIX-salget var på 65,7 MSEK, en stigning på 39% år-til-år.
Reduceret tab: Tabet for perioden blev reduceret til 37,1 MSEK (mod 218,6 MSEK i 1. kvartal 2024), hjulpet af øget salg og omkostningsstyring.
Likviditetsposition: Kvartalet sluttede med 250,2 MSEK i kontanter og likvide midler, tilstrækkelig til drift frem til 4. kvartal 2025.
Reduceret tab: Tabet for perioden blev reduceret til 37,1 MSEK (mod 218,6 MSEK i 1. kvartal 2024), hjulpet af øget salg og omkostningsstyring.
Likviditetsposition: Kvartalet sluttede med 250,2 MSEK i kontanter og likvide midler, tilstrækkelig til drift frem til 4. kvartal 2025.
24/4 2025 11:11 exitnu 0126048 Hansa Biopharma AB: Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2025:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=gvTS9Iuw
https://event.choruscall.com/mediaframe/webcast.html?webcastid=gvTS9Iuw
